INNOGEN-B(02591): The clinical trial application for the new veterinary drug Isubpagrulupeptide has been accepted.

INNOGEN-B (02591) announced that on February 4, 2026, the company's core product, Insupaglucide for the treatment of diabetes in pets, has had its new veterinary drug clinical trial application officially accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China. It is expected that Phase I clinical trials will start in the first quarter of 2026. The board of directors believes that the development of drugs for pet diabetes has great potential. As people are increasingly willing to spend money to extend the lifespan of their pets, the board of directors believes that such research and development is in line with the group's long-term business development strategy and will lay a solid foundation for the group to enter the pet pharmaceutical field in the future. The group has complied with all relevant standards and regulatory requirements for veterinary drug research and registration set by the Ministry of Agriculture, and has successfully completed relevant preclinical trials. Based on the results of the preclinical trials, Insupaglucide has made positive progress in the management of diabetes in pets in terms of efficacy and safety, providing a reasonable basis for subsequent clinical trials and registration applications for the drug.